Your browser doesn't support javascript.
loading
Genetic features of B-cell lymphoblastic lymphoma with TCF3-PBX1.
Shirai, Ryota; Osumi, Tomoo; Sato-Otsubo, Aiko; Nakabayashi, Kazuhiko; Mori, Takeshi; Yoshida, Masanori; Yoshida, Kaoru; Kohri, Mika; Ishihara, Takashi; Yasue, Shiho; Imamura, Toshihiko; Endo, Mikiya; Miyamoto, Satoshi; Ohki, Kentaro; Sanada, Masashi; Kiyokawa, Nobutaka; Ogawa, Seishi; Yoshioka, Takako; Hata, Kenichiro; Takagi, Masatoshi; Kato, Motohiro.
Afiliação
  • Shirai R; Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
  • Osumi T; Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Sato-Otsubo A; Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
  • Nakabayashi K; Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
  • Mori T; Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
  • Yoshida M; Department of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Tokyo, Japan.
  • Yoshida K; Department of Hematology and Oncology, Hyogo Prefectural Kobe children's Hospital, Kobe, Japan.
  • Kohri M; Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
  • Ishihara T; Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Yasue S; Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
  • Imamura T; Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
  • Endo M; Department of Pediatrics, Nara Medical University, Kashihara, Japan.
  • Miyamoto S; Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.
  • Ohki K; Department of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.
  • Sanada M; Department of Pediatrics, Iwate Medical University, Morioka, Japan.
  • Kiyokawa N; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan.
  • Ogawa S; Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
  • Yoshioka T; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Hata K; Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
  • Takagi M; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Kato M; Department of Pathology, National Center for Child Health and Development, Tokyo, Japan.
Cancer Rep (Hoboken) ; 5(9): e1559, 2022 09.
Article em En | MEDLINE | ID: mdl-34553842
ABSTRACT

BACKGROUND:

Lymphoblastic lymphoma (LBL) and acute lymphoblastic leukemia (ALL) are categorized as the same entity under precursor lymphoid neoplasms in the World Health Organization classification. However, compared to B-cell ALL, the molecular genetic makeup of B-cell LBL remains to be understood, mainly due to its rarity. We performed whole exome sequencing (WES) on seven patients with TCF3-PBX1-positive B-cell LBL.

METHODS:

WES was performed using DNA extracted from tumor specimens and paired blood samples at remission for six patients, and tumor-only analysis was performed for one patient whose remission sample was not available. For one patient, a relapsed sample was also analyzed.

RESULTS:

KMT2D variants and 6q LOH were found as recurrent alterations. Somatic variants of KMT2D were identified in three of the seven patients. Of note, the two patients with heterozygous nonsense variant of KMT2D were at stage III, without bone marrow infiltration. 6q LOH was also identified in two others, out of the seven patients. The common 6q deleted region of the two patients ranged from 6q12 to 6q16.3. Both patients had bone marrow infiltration. Analysis of recurrent case also revealed that the relapsed clone might be derived from a minor clone of the bone marrow at diagnosis.

CONCLUSION:

In this study, through WES for seven patients with TCF3-PBX1-positive B-LBL, we identified KMT2D mutations and 6q LOH as recurrent alterations. In order to elucidate the relationship between these recurrent alterations and disease specificity or outcomes, further studies comparing with TCF3-PBX1-positive B-ALL are required.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas de Fusão Oncogênica / Leucemia-Linfoma Linfoblástico de Células Precursoras Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas de Fusão Oncogênica / Leucemia-Linfoma Linfoblástico de Células Precursoras Idioma: En Ano de publicação: 2022 Tipo de documento: Article